Sox, you are wrong. The first cohort is for SAFETY, not efficacy. The dose is very low. "What is to be gained" by continuing? More data as to how long the drug can be used without side effects. There is no reason to discontinue dosing the first cohort, and every reason to continue with dosage, whether or not any efficacy is perceived. It would be very unusual for such a low dose to show efficacy. The first dose, as press releases and emails from the company made clear, is intentionally at an EXTREMELY low dose because safety needs to be demonstrated. That is why the successive cohorts get a "rapid escalation" of the dose.

Frankly I am tired of this tea leaf reading. Does it not occur to anyone that a harried and overly busy NP answering a bunch of emails while he is also doing many other tasks in helping to run trials,  may have mis-written -- in other words, may have been mistaken in his email?